Parkinson's Disease Clinical Trial
— EARLY-PUMPOfficial title:
Apomorphine Pump in Early Stage of Parkinson's Disease
Verified date | November 2023 |
Source | Rennes University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of the study is to assess the use of the apomorphine pump in earlier stages of Parkinson' Disease (PD), when motor complications have just developed and before patients are significantly affected in their social and occupational functioning. The investigators hypothesize that apomorphine pump is superior in terms of positive impact on quality of life (QoL) to oral medical therapy alone at a relatively early stage of PD, before the appearance of severe disabling motor complications thus favoring the maintain of patients' social and occupational status with a significant positive economic impact of the health system.
Status | Active, not recruiting |
Enrollment | 134 |
Est. completion date | January 30, 2025 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Adults aged = 65 years, - Idiopathic PD (According to British Brain Bank Criteria) without any other known or suspected cause of Parkinsonism, - Hoehn and Yahr stage = 2.5 in the best ON, - Disease duration = 4 years, - Presence of fluctuations and/or dyskinesias for no more than 3 years, - One of the two following forms of impairment : - Impairment in activities of daily living (MDS-UPDRS II>6) due to PD-symptoms despite medical treatment in the worst condition or, - Impairment of social and occupational functioning (measured with SOFAS) due to PD-symptoms despite medical treatment (51-80%), - PDQ39 completed, - Able to understand and remember the component of the study, - Written informed consent, - Patients covered with social insurance. Exclusion Criteria: - Dementia (MoCA < 22), - Major uncontrolled depression at the time of assessment (BDI > 25) or Bipolar disease, - Active hallucinations or history of hallucinations in the past year, - Need for nursing care, - Previous use of apomorphine pump treatment, - History of respiratory depression, - History of deep brain stimulation or lesional surgery for PD or intrajejunal L-Dopa, - Presence of severe freezing or clinically relevant postural instability leading to falls during the ON state, - Symptomatic clinically relevant and medically uncontrolled orthostatic hypotension, - Clinically relevant hepatic dysfunction (total bilirubin >2.0 mg/dL, Alanine Amino Transferase (ALT) and Aspartate Amino Transferase (AST) >2 times the upper limit of normal), - Clinically relevant renal dysfunction (serum creatinine >2.0 mg/dL), - Pregnant and breastfeeding women, - Hypersensitivity to apomorphine or any excipients of the medicinal product, - Concomitant therapy or within 28 days prior to baseline with : alpha-methyl dopa, metoclopramide, reserpine, neuroleptics (except Clozapine), methylphenidate, or amphetamine, intrajejunal Ldopa, - History or current drug or alcohol abuse or dependencies, - Patients with a borderline QT interval corrected for heart rate according to Bazett's formula (QTc) of >470 ms for male and >480 ms for female at screening or history of long QT syndrome; - Adults legally protected (under judicial protection, guardianship or supervision), persons deprived of their liberty. |
Country | Name | City | State |
---|---|---|---|
France | Amiens University Hospital | Amiens | |
France | Bayonne Côte Basque Hospital | Bayonne | |
France | Pellegrin University Hospital | Bordeaux | |
France | Pierre Wertheimer Hospital | Bron | |
France | Caen University Hospital | Caen | |
France | Clermont-Ferrand University Hospital | Clermont-Ferrand | |
France | Lille University Hospital | Lille | |
France | APHM, hospital of Timone | Marseille | |
France | Clinique Beau-Soleil | Montpellier | |
France | Montpellier University Hospital | Montpellier | |
France | Nancy University Hospital | Nancy | |
France | Laennec Hospital | Nantes | |
France | Pasteur 2 University Hospital | Nice | |
France | Caremeau University Hospital | Nîmes | |
France | Pitié-Salpêtriere Hospital | Paris | |
France | Poitiers University Hospital | Poitiers | |
France | Rennes University Hospital | Rennes | |
France | Saint-Etienne University Hospital | Saint- Etienne | |
France | Hautepierre University Hospital | Strasbourg | |
France | Purpan University Hospital | Toulouse |
Lead Sponsor | Collaborator |
---|---|
Rennes University Hospital |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Difference in the Parkinson's Disease Quality of Life Questionnaire (PDQ39) summary index between the baseline assessment and the assessment at 12 months' follow up | 12 months | ||
Secondary | Change in the Patient Global Impression of Change (PGIC) | 12 months | ||
Secondary | Change in the Neurologist Global Impression of change (CGI-I) | 12 months | ||
Secondary | Change in non-motor aspects of experiences of daily living (MDS-UPDRS I) between the baseline assessment and the assessment at 12 months' follow up | 12 months | ||
Secondary | Change in motor aspects of experiences of daily in "on" and "off" medication (MDS-UPDRS II) between the baseline assessment and the assessment at 12 months' follow up | 12 months | ||
Secondary | Change in motor examination during "on" periods (MDS-UPDRS III) between the baseline assessment and the assessment at 12 months' follow up | 12 months | ||
Secondary | Change in motor complications with MDS-UPDRS IV between the baseline assessment and the assessment at 12 months' follow up | 12 months | ||
Secondary | Change in number of hours per day in the "best ON" state between the baseline assessment and the assessment at 12 months' follow up | 12 months | ||
Secondary | Change in number of hours per day in "ON" with dyskinesia between the baseline assessment and the assessment at 12 months' follow up | 12 months | ||
Secondary | Change in number of hours per day in "OFF" state between the baseline assessment and the assessment at 12 months' follow up | 12 months | ||
Secondary | Change in number of Sleeping-hours per day between the baseline assessment and the assessment at 12 months' follow up | 12 months | ||
Secondary | Change in Score of the Non-Motor Symptoms Scales (NMSS) for PD between the baseline assessment and the assessment at 12 months' follow up | 12 months | ||
Secondary | Change in psychosocial functioning PD (SCOPA-PS) between the baseline assessment and the assessment at 12 months' follow up | 12 months | ||
Secondary | Changes in score of depressive symptoms (BDI) between the baseline assessment and the assessment at 12 months' follow up | 12 months | ||
Secondary | Change in occurrence of anxiety (STAI-S) between the baseline assessment and the assessment at 12 months' follow up | 12 months | ||
Secondary | Change in pain assessed on the Visual Analog Scale (VAS) between the baseline assessment and the assessment at 12 months' follow up | 12 months | ||
Secondary | Change in cognitive function between the baseline assessment and the assessment at 12 months' follow up | Change in cognitive function assessed by the Neuroscience Parkinson network's (NS-PARK) battery test | 12 months | |
Secondary | Change in apathy assessed on the Apathy Scale between the baseline assessment and the assessment at 12 months' follow up | 12 months | ||
Secondary | Change in apathy assessed on the short version of Lille Apathy Rating Scale (LARS) between the baseline assessment and the assessment at 12 months' follow up | 12 months | ||
Secondary | Change of dose for treatments assessed by levodopa (L-DOPA) equivalents between the baseline assessment and the assessment at 12 months' follow up | 12 months | ||
Secondary | Change in behavioral symptoms assessed by Ardouin Scale between the baseline assessment and the assessment at 12 months' follow up | 12 months | ||
Secondary | Frequency, type and severity of therapy-related adverse events | 12 months | ||
Secondary | Skin changes assessed by a clinical exam | 12 months | ||
Secondary | Full blood count | 12 months | ||
Secondary | Epworth Sleepiness Scale | 12 months | ||
Secondary | Incremental Cost-Effectiveness Ratio (ICER) | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02915848 -
Long-term Stability of LFP Recorded From the STN and the Effects of DBS
|
||
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Terminated |
NCT02688465 -
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
|
Phase 4 | |
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Active, not recruiting |
NCT04006210 -
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
|
Phase 3 | |
Completed |
NCT02562768 -
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
|
Phase 1 | |
Completed |
NCT00105508 -
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
|
Phase 3 | |
Completed |
NCT00105521 -
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
|
Phase 3 | |
Recruiting |
NCT06002581 -
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
|
N/A | |
Completed |
NCT02236260 -
Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation
|
N/A | |
Completed |
NCT00529724 -
Body Weight Gain, Parkinson, Subthalamic Stimulation
|
Phase 2 | |
Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
Completed |
NCT03703570 -
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
|
Phase 2 | |
Completed |
NCT03462680 -
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
|
N/A | |
Completed |
NCT02837172 -
Diagnosis of PD and PD Progression Using DWI
|
||
Not yet recruiting |
NCT04046276 -
Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease
|
N/A | |
Recruiting |
NCT02952391 -
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol
|
N/A | |
Active, not recruiting |
NCT02937324 -
The CloudUPDRS Smartphone Software in Parkinson's Study.
|
N/A | |
Completed |
NCT02874274 -
Vaccination Uptake (VAX) in PD
|
N/A | |
Terminated |
NCT02894567 -
Evaluation of Directional Recording and Stimulation Using spiderSTN
|
N/A |